AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1-9 (Cancelled)

10. (Currently amended) A mutant *ras* peptide having a size of 8 to 13 amino acids, comprising

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val (SEQ ID NO:14); wherein Xaa_1 is the amino acid lysine or tyrosine; wherein Xaa_2 is an amino acid;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine; with the proviso that when Xaa_2 is valine, Xaa_1 is tyrosine

and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

11. (Previously presented) The mutant *ras* peptide according to claim 10 wherein the peptide comprises an amino acid sequence of 13 amino acids.

12. (Previously presented) The mutant *ras* peptide according to claim 10 wherein the peptide comprises an amino acid sequence of 10 amino acids.

13. (Original) The mutant *ras* peptide according to claim 10, 11 or 12 wherein Xaa_1 is tyrosine.

14. (Original) The mutant *ras* peptide according to claim 10, 11, 12 or 13

wherein Xaa_1 is selected from the group consisting of valine, tryptophan, leucine, tyrosine and phenylalanine.

15. (Original) The mutant *ras* peptide according to claim 10, 11, 12, 13 or 14 wherein Xaa_1 is tyrosine and Xaa_3 is aspartic acid.

16. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, 13 or 14 wherein Xaa_1 is tyrosine and Xaa_3 is valine.

17. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, 13, or 14 wherein Xaa_1 is tyrosine and Xaa_3 is cysteine.

18. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, or 14 wherein Xaa_1 is lysine and Xaa_3 is aspartic acid.

19. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, or 14 wherein Xaa_1 is lysine and Xaa_3 is valine.

20. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, or 14 wherein Xaa_1 is lysine and Xaa_3 is cysteine.

21. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, 18 or 19 wherein Xaa_1 is lysine and Xaa_3 is tryptophane.

22. (Withdrawn) The mutant *ras* peptide according to claim 10, 11, 12, 15, 16 or 17 wherein Xaa_1 is tyrosine and Xaa_3 is tryptophan.

23. (Withdrawn) The mutant *ras* peptide according to claim 10, 11 or 12 wherein Xaa_1 is lysine, Xaa_2 tryptophan, and Xaa_3 is selected from the group consisting of aspartic acid, valine and cysteine.

24. (Withdrawn) The mutant *ras* peptide according to claim 10, 11 or 12 wherein Xaa_1 is tyrosine, Xaa_2 is tryptophan, and Xaa_3 is selected from the group consisting of aspartic acid, valine and cysteine.

25. (Previously presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide according to claims 10-23 or 24 and a carrier molecule, said carrier molecule enhances the immunogenicity of the peptide.

26 (Cancelled)

27. (Currently amended) An immunogen for eliciting a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide according to claims 10-23 or 24 or combination thereof, [[said]] <u>wherein the</u> immunogen elicits a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

28-31 (Cancelled)

32. (Previously presented) A pharmaceutical composition comprising the mutant *ras* peptide of claims 10-24 and a pharmaceutically acceptable carrier.

33. (Previously presented) The pharmaceutical composition according to claim 32, further comprising a biological response modifier.

34. (Currently amended) The ~~Pharmaceutical~~ pharmaceutical composition according to claims 32 or 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosyphoryl lipid A.

35-65 (Cancelled)

66. (Previously presented) The mutant *ras* peptide-carrier molecule conjugate according to claim 25, wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A and poly-L-lysine.

67. (Previously presented) The mutant *ras* peptide-carrier molecule conjugate according to claim 25, wherein the carrier molecule is tetanus toxoid.

68. (Previously presented) The pharmaceutical composition according to claim 33, wherein the biological response modifier is interleukin 2.

69 (Cancelled)

70. (Previously presented) The pharmaceutical composition according to claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF, β_2-microglobulin, or combinations thereof.